Literature DB >> 7833510

Physiologic and pharmacologic factors that affect myocardial relaxation.

L Vittone1, C Mundiña-Weilenmann, A Mattiazzi, H Cingolani.   

Abstract

Evaluation of the myocardial relaxation has become important in the last years. An impaired relaxation may precede contractile dysfunctions and even cause heart failure. To treat this impaired lusitropism it is necessary to properly assess the lusitropic state of the heart and understand how drugs affect the cellular mechanisms underlying myocardial relaxation (sarcoplasmic reticulum function, Ca2+ fluxes through the sarcolemma and myofilament Ca2+ sensitivity). Current information regarding these issues is provided in this review. The relative usefulness of the mechanical parameters used to evaluate the lusitropic state of the heart in experimental models applied in pharmacology will also be discussed.

Entities:  

Mesh:

Year:  1994        PMID: 7833510     DOI: 10.1016/1056-8719(94)90011-6

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  3 in total

1.  Biphasic changes in relaxation following reperfusion after myocardial ischemia.

Authors:  S M Mosca; M Carriquiriborde; H E Cingolani
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

2.  Differential effects of tert-butyl-benzohydroquinone, a putative SR Ca2+ pump inhibitor, on isometric relaxation during the staircase in the rabbit and rat ventricle.

Authors:  S Baudet; A Khammari; J Noireaud; H Le Marec
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

3.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.